| P50 | author | In Gab Jeong | Q86850546 |
| | Peter C. Searson | Q42818002 |
| | Kwan Hyi Lee | Q41731890 |
| | Choung-Soo Kim | Q56635696 |
| P2093 | author name string | Sang Hoon Song | |
| | Minhong Jeun | |
| | Benedict J Kang | |
| | Gun Hyuk Jang | |
| P2860 | cites work | PET/CT in prostate cancer: an unmet clinical need | Q95622223 |
| | An investigation into the human serum "interactome" | Q24294835 |
| | Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement | Q24676201 |
| | TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions | Q24678489 |
| | Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review | Q26828933 |
| | Cancer statistics, 2015 | Q27860576 |
| | The human plasma proteome: history, character, and diagnostic prospects | Q28218148 |
| | Rapid detection of semenogelin by one-step immunochromatographic assay for semen identification | Q28257724 |
| | Role of the TMPRSS2-ERG gene fusion in prostate cancer | Q28269156 |
| | Nanoscale bacteriophage biosensors beyond phage display | Q28389760 |
| | Immunomagnetic nanoparticle-based assays for detection of biomarkers | Q28391829 |
| | Gleason grading and prognostic factors in carcinoma of the prostate | Q29306305 |
| | Cancer nanotechnology: opportunities and challenges | Q29615481 |
| | Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 | Q29615661 |
| | Screening and prostate-cancer mortality in a randomized European study | Q29617485 |
| | Bioassay of prostate-specific antigen (PSA) using microcantilevers. | Q30708669 |
| | High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures | Q33221138 |
| | Urine collection and processing for protein biomarker discovery and quantification | Q33780855 |
| | Systematic quantitative characterization of cellular responses induced by multiple signals | Q33915637 |
| | Single-wall carbon nanotube forest arrays for immunoelectrochemical measurement of four protein biomarkers for prostate cancer | Q33982421 |
| | State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines | Q34045119 |
| | Virus-polymer hybrid nanowires tailored to detect prostate-specific membrane antigen | Q34160391 |
| | Noninvasive detection of clinically occult lymph-node metastases in prostate cancer | Q34207093 |
| | Scanometric microRNA array profiling of prostate cancer markers using spherical nucleic acid-gold nanoparticle conjugates | Q34226854 |
| | Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. | Q34227677 |
| | Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. | Q34291551 |
| | Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter | Q34323096 |
| | Assessment of screening for prostate cancer using the digital rectal examination. | Q34522776 |
| | Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer | Q34577447 |
| | Core biopsy instrument in the diagnosis of prostate cancer: superior accuracy to fine needle aspiration | Q41983624 |
| | Gum arabic-coated radioactive gold nanoparticles cause no short-term local or systemic toxicity in the clinically relevant canine model of prostate cancer | Q41990210 |
| | New tests for prostate cancer may be nearing the clinic | Q43055323 |
| | A novel sensitive immunoassay by nucleic acid barcode dot and its application in the detection of prostate-specific antigen | Q43225790 |
| | Think modular: a simple apoferritin-based platform for the multifaceted detection of pancreatic cancer. | Q43527268 |
| | Incremental value of magnetic resonance imaging for clinically high risk prostate cancer in 922 radical prostatectomies | Q43656664 |
| | The contribution of transrectal ultrasonography in the early diagnosis of prostate cancer | Q43816706 |
| | Quantification of cardiovascular disease biomarkers via functionalized magnetic beads and on-demand detachable quantum dots | Q43890271 |
| | Preoperative evaluation of localized prostatic carcinoma by transrectal ultrasonography | Q43991894 |
| | Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. | Q44018378 |
| | Magnetic bead-based reverse colorimetric immunoassay strategy for sensing biomolecules. | Q44364713 |
| | Screening for prostate cancer: PSA blood test, rectal examination, and ultrasound | Q44498803 |
| | A strategy to decorate porous polymer monoliths with graphene oxide and graphene nanosheets | Q44632211 |
| | Immunoassay of total prostate-specific antigen using europium(III) nanoparticle labels and streptavidin-biotin technology | Q45190070 |
| | PSA, PCA3 and the phi losophy of prostate cancer management | Q45295846 |
| | Maximizing specificity and yield of PCR by the quantum dot itself rather than property of the quantum dot surface. | Q46011953 |
| | PSMA PET in Prostate Cancer. | Q46021602 |
| | Label-free and reagentless electrochemical detection of microRNAs using a conducting polymer nanostructured by carbon nanotubes: application to prostate cancer biomarker miR-141. | Q46265583 |
| | Real-time and label-free detection of the prostate-specific antigen in human serum by a polycrystalline silicon nanowire field-effect transistor biosensor | Q46290827 |
| | Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer. | Q46334365 |
| | Direct electronic detection of prostate-specific antigen in serum | Q46346996 |
| | A novel electrochemical immunosensor based on colabeled silica nanoparticles for determination of total prostate specific antigen in human serum | Q46461722 |
| | A highly sensitive prostate-specific antigen immunosensor based on gold nanoparticles/PAMAM dendrimer loaded on MWCNTS/chitosan/ionic liquid nanocomposite | Q46504817 |
| | Prostate-specific antigen immunosensing based on mixed self-assembled monolayers, camel antibodies and colloidal gold enhanced sandwich assays | Q46631852 |
| | Combined role of transrectal ultrasonography, gleason score, and prostate-specific antigen in predicting organ-confined prostate cancer | Q46786173 |
| | Integrated microfluidic systems with an immunosensor modified with carbon nanotubes for detection of prostate specific antigen (PSA) in human serum samples | Q46830723 |
| | Label-free electrochemical immunosensor for prostate-specific antigen based on silver hybridized mesoporous silica nanoparticles. | Q46839076 |
| | Enhancement of sensitivity and specificity by surface modification of carbon nanotubes in diagnosis of prostate cancer based on carbon nanotube field effect transistors | Q47690663 |
| | A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis | Q48081174 |
| | Facile solvothermal preparation of monodisperse gold nanoparticles and their engineered assembly of ferritin-gold nanoclusters. | Q50482949 |
| | Harnessing immunomagnetic separation and quantum dot-based quantification capacities for the enumeration of absolute levels of biomarker. | Q50890413 |
| | Detection of MicroRNAs using target-guided formation of conducting polymer nanowires in nanogaps. | Q51030966 |
| | Microfluidic tool based on the antibody-modified paramagnetic particles for detection of 8-hydroxy-2'-deoxyguanosine in urine of prostate cancer patients. | Q51514589 |
| | Microfluidic chip coupled with modified paramagnetic particles for sarcosine isolation in urine. | Q51530672 |
| | Highly sensitive chemiluminescence immunoassay on chitosan membrane modified paper platform using TiO2 nanoparticles/multiwalled carbon nanotubes as label. | Q51533964 |
| | Prostate specific antigen detection using microgapped electrode array immunosensor with enzymatic silver deposition. | Q51782614 |
| | Applicability of Nanotrap Sg as a semen detection kit before male-specific DNA profiling in sexual assaults. | Q51812289 |
| | Transrectal ultrasonography in prostatic cancer: interexaminer variability of interpretation. | Q52897131 |
| | Imaging prostate cancer with 11C-choline PET/CT. | Q53526446 |
| | Amplified quenching of electrochemiluminescence from CdS sensitized TiO2 nanotubes by CdTe-carbon nanotube composite for detection of prostate protein antigen in serum. | Q53888184 |
| | Femtomolar detection of prostate-specific antigen: an immunoassay based on surface-enhanced Raman scattering and immunogold labels. | Q53913375 |
| | TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. | Q54561352 |
| | Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. | Q54566910 |
| | TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. | Q54571377 |
| | Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. | Q54611063 |
| | Ultra-sensitive detection of mutated papillary thyroid carcinoma DNA using square wave stripping voltammetry method and amplified gold nanoparticle biomarkers. | Q54788270 |
| | Transrectal ultrasonography for the early detection and staging of prostate cancer | Q37971060 |
| | Role of transrectal ultrasonography in prostate cancer | Q38057442 |
| | Urinary exosomes: a reservoir for biomarker discovery and potential mediators of intrarenal signalling | Q38058047 |
| | Applications of nanotechnology for immunology | Q38123937 |
| | Seminal plasma as a diagnostic fluid for male reproductive system disorders | Q38202841 |
| | EphrinA I-targeted nanoshells for photothermal ablation of prostate cancer cells | Q38498023 |
| | Antitumor activity of tripterine via cell-penetrating peptide-coated nanostructured lipid carriers in a prostate cancer model | Q39062936 |
| | Diagnosis and Staging of Prostatic Cancer by Transrectal Ultrasonography. A Preliminary Study | Q39204567 |
| | Highly sensitive immunosensing of prostate-specific antigen based on ionic liquid-carbon nanotubes modified electrode: application as cancer biomarker for prostate biopsies. | Q39227227 |
| | Transrectal ultrasonography in the staging of localized prostatic carcinoma. A pilot study | Q39242189 |
| | Early prostate cancer: diagnostic costs of screening transrectal US and digital rectal examination | Q39290713 |
| | Routine screening for prostate cancer using the digital rectal examination | Q39298324 |
| | Needle aspiration and core biopsy of prostate cancer: comparative evaluation with biplanar transrectal US guidance | Q39302687 |
| | PSA as a screening test for prostate cancer. | Q39369907 |
| | Prostate-specific antigen and digital rectal examination in screening for prostate cancer: a community-based study. | Q39370289 |
| | Mn-doped ZnSe d-dots-based α-methylacyl-CoA racemase probe for human prostate cancer cell imaging | Q39412972 |
| | Prostate cancer detection at low prostate specific antigen | Q39529729 |
| | Extended 12-core prostate biopsy increases both the detection of prostate cancer and the accuracy of Gleason score | Q39737762 |
| | Cancer detection with TRUS-guided 10-core biopsy of the prostate. an institutional assessment at the first, repeated and surgical specimen biopsy. | Q39766659 |
| | Transrectal ultrasonography of the prostate and prostate cancer--an update. | Q39843687 |
| | Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3. | Q39954842 |
| | Biochemical markers in prostatic cancer | Q40110206 |
| | Ten-core versus 16-core transrectal ultrasonography guided prostate biopsy for detection of prostatic carcinoma: a prospective comparative study in Indian population | Q40162083 |
| | TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming | Q40213178 |
| | Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer | Q40236516 |
| | TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer | Q40236533 |
| | Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen | Q40747388 |
| | Biopsy Gleason score: how does it correlate with the final pathological diagnosis in prostate cancer? | Q40899430 |
| | Quantitative characterization of the lipid encapsulation of quantum dots for biomedical applications | Q41857876 |
| | Developing a nanoparticle test for prostate cancer scoring | Q41900218 |
| | Nanoporous gold as a solid support for protein immobilization and development of an electrochemical immunoassay for prostate specific antigen and carcinoembryonic antigen | Q41903396 |
| | Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo | Q34584347 |
| | PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy | Q34611796 |
| | Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer | Q34612941 |
| | Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm | Q34763799 |
| | Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy | Q34792453 |
| | Sequencing hormonal ablation and radiotherapy in prostate cancer: a molecular and therapeutic prespective (Review). | Q34957065 |
| | The use of PCA3 in the diagnosis of prostate cancer | Q34979800 |
| | The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer | Q34984413 |
| | CDKN2D-WDFY2 is a cancer-specific fusion gene recurrent in high-grade serous ovarian carcinoma. | Q35133251 |
| | Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy | Q35254451 |
| | Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up | Q35677465 |
| | PET and prostate cancer | Q35926932 |
| | Urine proteomics: the present and future of measuring urinary protein components in disease | Q35929449 |
| | Quantitative molecular profiling of biomarkers for pancreatic cancer with functionalized quantum dots | Q35965742 |
| | -The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid | Q36016842 |
| | Hybrids of a genetically engineered antibody and a carbon nanotube transistor for detection of prostate cancer biomarkers | Q36060512 |
| | Assessment of the American Joint Committee on Cancer staging (sixth and seventh editions) for clinically localized prostate cancer treated with external beam radiotherapy and comparison with the National Comprehensive Cancer Network risk-stratificat | Q36133745 |
| | Prostate stem cell antigen-targeted nanoparticles with dual functional properties: in vivo imaging and cancer chemotherapy | Q36152452 |
| | Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner. | Q36165436 |
| | Neuroscience nanotechnology: progress, opportunities and challenges | Q36350205 |
| | Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy | Q36496050 |
| | Designed DNA molecules: principles and applications of molecular nanotechnology | Q36504884 |
| | Improving cancer detection by prostate biopsy: the role of core number and site | Q36619283 |
| | Advances in urinary proteome analysis and biomarker discovery | Q36747925 |
| | Sub-nanomolar detection of prostate-specific membrane antigen in synthetic urine by synergistic, dual-ligand phage. | Q36931769 |
| | The present and future of prostate cancer urine biomarkers | Q37007392 |
| | Current status of transrectal ultrasonography in the detection of prostate cancer | Q37089348 |
| | Magnetic nanoparticles of Fe3O4 enhance docetaxel-induced prostate cancer cell death | Q37120640 |
| | Nanotechnology-novel therapeutics for CNS disorders | Q37173643 |
| | Gastrin releasing protein receptor specific gold nanorods: breast and prostate tumor avid nanovectors for molecular imaging | Q37236396 |
| | Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy | Q37413491 |
| | Lymphotropic nanoparticle enhanced MRI for the staging of genitourinary tumors. | Q37677556 |
| | Urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine as a biomarker in type 2 diabetes | Q37912415 |
| | Treating metastatic cancer with nanotechnology | Q37970910 |
| | Digital rectal examination in the early detection of prostate cancer. | Q37971058 |
| | Resin-based micropipette tip for immunochromatographic assays in urine samples | Q83176467 |
| | A three-layer competition-based giant magnetoresistive assay for direct quantification of endoglin from human urine | Q83644280 |
| | An aptamer based resonance light scattering assay of prostate specific antigen | Q84030598 |
| | Discrimination of breast cancer by measuring prostate-specific antigen levels in women's serum | Q84139401 |
| | Nanotechnology: Tag teams | Q84554463 |
| | Barcode lateral flow immunochromatographic strip for prostate acid phosphatase determination | Q84862934 |
| | Evaluation of the 7th American Joint Committee on cancer TNM staging system for prostate cancer in point of classification of bladder neck invasion | Q85640609 |
| | Nanotechnology: Biological proteins knock nanoparticles off target | Q86386110 |
| | New technology: nanotechnology targets cancer cells | Q86536828 |
| | Microfabricated tin-film electrodes for protein and DNA sensing based on stripping voltammetric detection of Cd(II) released from quantum dots labels | Q86540489 |
| | Cancer nanotechnology: small, but heading for the big time | Q55981414 |
| | Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial | Q56804990 |
| | TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion | Q57693484 |
| | Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification | Q57693655 |
| | Diversity of TMPRSS2-ERG fusion transcripts in the human prostate | Q57694515 |
| | Nanotechnology opens up new realm of detection in GBM | Q58195087 |
| | Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin | Q59364974 |
| | Diagnostic value of transrectal ultrasonography in prostatic cancer | Q68191327 |
| | Formula to Estimate Risk of Pelvic Lymph Node Metastasis from the Total Gleason Score for Prostate Cancer | Q68453699 |
| | Biopsy techniques and cytology in prostate cancer | Q68567098 |
| | Transrectal ultrasonography for prostatic cancer. II. The response of the prostate to definitive radiotherapy | Q68858325 |
| | Transrectal prostatic ultrasonography: comparison of linear array and radial scanners | Q69381284 |
| | Transrectal ultrasonography for prostatic cancer: its value in staging and monitoring the response to radiotherapy and chemotherapy | Q69889856 |
| | Operable prostatic carcinoma: correlations among clinical stage, pathological stage, gleason histological score and early disease-free survival | Q70043455 |
| | Transrectal ultrasonography in the followup of prostatic carcinoma patients | Q70518885 |
| | Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose | Q71095669 |
| | Effect of the number of core biopsies of the prostate on predicting Gleason score of prostate cancer | Q71122143 |
| | Transrectal ultrasonography in the followup of prostatic carcinoma patients: a new prognostic parameter? | Q71304095 |
| | Transrectal ultrasonography in the evaluation of patients with prostatic carcinoma | Q71335060 |
| | The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer | Q71703275 |
| | Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer | Q71736184 |
| | The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate Cancer | Q72083446 |
| | Screening for prostate cancer utilizing the prostate-specific antigen (PSA) | Q72104456 |
| | Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group | Q72156114 |
| | Digital rectal examination screening for prostate cancer | Q72902153 |
| | Pretreatment staging of clinically localized prostate cancer. American College of Radiology. ACR Appropriateness Criteria | Q73091602 |
| | An electrochemical metalloimmunoassay based on a colloidal gold label | Q73255327 |
| | Colloidal gold as an electrochemical label of streptavidin-biotin interaction | Q73543564 |
| | Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease | Q73855715 |
| | Use of the "SMITEST" PSA card to identify the presence of prostate-specific antigen in semen and male urine | Q74413551 |
| | Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy | Q75435933 |
| | Outcome evaluation of the 1997 American Joint Committee on Cancer staging system for prostate carcinoma treated by radiation therapy | Q77387033 |
| | PSA screening said to reduce prostate-cancer deaths, or does it? | Q77747423 |
| | PSA screening for prostate cancer: the current controversy | Q77949167 |
| | Effects of storage time and exogenous protease inhibitors on plasma protein levels | Q80064761 |
| | Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88 | Q80859225 |
| | Inadequacies of the current American Joint Committee on cancer staging system for prostate cancer | Q82045881 |
| | Quantum dot-based immunosensor for the detection of prostate-specific antigen using fluorescence microscopy | Q82911604 |
| | The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer | Q83103181 |
| | PCA3 score vs PSA free/total accuracy in prostate cancer diagnosis at repeat saturation biopsy | Q83135421 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nanomedicine | Q261659 |
| | prostate neoplasm | Q56014511 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 6555-69 | |
| P577 | publication date | 2015-10-19 | |
| P1433 | published in | International Journal of Nanomedicine | Q6051502 |
| P1476 | title | Diagnosis of prostate cancer via nanotechnological approach | |
| P478 | volume | 10 | |